Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1628481 Target Snapshot

Apelin receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,953Compounds
139Assays
5Approved Drugs
6,429.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Apelin receptor shows clinical signal disease relevance led by diabetes mellitus. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P35414. Start with diabetes mellitus, then reuse UniProt P35414 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetes mellitus, then reuse UniProt P35414 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
diabetes mellitus

Apelin receptor shows clinical signal disease relevance led by diabetes mellitus. 1 linked drug remains visible in the same block.

Start review with diabetes mellitus because it currently carries clinical signal support. Linked drugs include APELIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Apelin receptor as ChEMBL target CHEMBL1628481, mapped to UniProt P35414. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Apelin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1628481
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35414
Apelin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Apelin receptor is the right protein anchor across sources, using UniProt P35414 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetes mellitus is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameApelin receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP35414
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelApelin receptor
UniProt AccessionP35414
Component TypeProtein
Sequence Length380 aa

Apelin receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Apelin receptor, mapped to UniProt P35414. Sequence length is 380 aa.

Mapped IDP35414
Review nameApelin receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Apelin receptor shows clinical signal disease relevance led by diabetes mellitus.

Clinical signal Phase I
diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugAPELIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetes mellitus because it currently carries clinical signal support. Linked drugs include APELIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetes mellitus
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC50160.0
KI289.0
EC505,979.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4851100 11.0 EC50 0.01 Preclinical
CHEMBL4878056 11.0 EC50 0.01 Preclinical
CHEMBL3184840 10.91 EC50 0.0122 Preclinical
CHEMBL3417384 10.8 Ki 0.016 Preclinical
CHEMBL4864542 10.7 EC50 0.02 Preclinical
CHEMBL4872345 10.7 EC50 0.02 Preclinical
CHEMBL5173464 10.7 EC50 0.02 Preclinical
CHEMBL5192130 10.7 EC50 0.02 Preclinical
CHEMBL5193130 10.7 EC50 0.02 Preclinical
CHEMBL5202635 10.7 EC50 0.02 Preclinical
Distribution

pChEMBL Value Distribution

72
5.0
107
5.5
302
6.0
553
6.5
816
7.0
781
7.5
1458
8.0
662
8.5
804
9.0
446
9.5
pChEMBL
Assay Landscape

Assay Landscape

139
Total Assays
3,052
Tested Compounds
4
Assay Types
Binding — 70 assays, 3,052 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 43 1,011 8.0
single protein format 14 6 7.1
assay format 11 2,033 8.2
cell membrane format 2 2 9.7
Functional — 65 assays, 450 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 56 412 7.4
assay format 7 37 7.9
cell membrane format 2 1 6.3
ADME — 2 assays, 24 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 24 6.2
Unassigned — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine